ClinicalTrials.gov
ClinicalTrials.gov Menu

Preventing HIV/Aids in Drug Abusing Youth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00680719
Recruitment Status : Completed
First Posted : May 20, 2008
Last Update Posted : August 5, 2014
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Oregon Research Institute

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This project involves two studies focusing on the engagement and treatment of adolescents diagnosed with substance use disorders. Study 1 will evaluate a promising parent-based engagement intervention, Community Reinforcement Training, designed to facilitate the entry of resistant drug-abusing adolescents in treatment. The approach will be compared with an Engagement As Usual intervention condition. Study 2 involves a controlled clinical trial evaluating the efficacy of an HIV/AIDS prevention intervention embedded in family-based drug abuse treatment for reducing HIV/AIDS risk behaviors and substance use. Adolescents who are successfully engaged in treatment through Study 1 will be randomly assigned to receive either family therapy alone or family therapy with the integrated HIV/AIDS prevention intervention. Both studies are being conducted in Portland, Oregon.

Condition or disease Intervention/treatment Phase
HIV Infections Behavioral: IBFT /HIV prevention Behavioral: IBFT Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 111 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preventing HIV/Aids in Tx-Resistant Drug-Abusing Youth
Study Start Date : June 2004
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: 1
Family Therapy plus HIV prevention
 Behavioral: IBFT /HIV prevention
Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
Active Comparator: 2
Family Therapy only.
 Behavioral: IBFT
Integrated Behavioral and Family Therapy (IBFT).


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Changes in adolescent's substance use. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Changes in HIV risk behaviors. [ Time Frame: 12 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Parents have an adolescent in the ages of 15-20 years.
  • Have had contact with the adolescent on at least 40% of the past 90 days.
  • Have some knowledge or evidence that the adolescent would meet DSM-IV diagnostic criteria for a substance abuse disorder.
  • Adolescent has explicitly refused to attend any intake or therapy sessions.
  • All parents' efforts to enter adolescent into treatment have failed, despite therapist's assistance.
  • Residence in Portland vicinity.
  • Sufficient residential stability to permit probable contact at follow-up. (e.g. not homeless at time of intake)

Exclusion Criteria:

  • Evidence of psychotic or organic state of sufficient severity to interfere with understanding of study instruments and procedures.
  • Adolescent has received residential drug treatment longer than a 2-week period in the past 90 days.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00680719


Locations
United States, Oregon
Oregon Research Institute Center for Family and Adolescent Research
Portland, Oregon, United States, 97205
Sponsors and Collaborators
Oregon Research Institute
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Holly B Waldron, Ph.D. Oregon Research Institute
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Oregon Research Institute
ClinicalTrials.gov Identifier: NCT00680719     History of Changes
Other Study ID Numbers: DA17023
First Posted: May 20, 2008    Key Record Dates
Last Update Posted: August 5, 2014
Last Verified: August 2014

Keywords provided by Oregon Research Institute:
substance abuse
HIV risk
Behavior and Mental Disorders
HIV Seronegativity

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases